Post

GID BIO’s results in randomized controlled Phase IIb clinical study support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee

While minimally invasive treatments transformed cardiology decades ago, advancements in orthopedic medicine are introducing potential alternatives to traditional surgery by applying cellular medicine therapies. GID BIO is focused on using...

Learn More

Post

GID BIO, a cellular medicine company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system

AMA grants two Category III CPT® codes, paving the way for reimbursement strategies   GID BIO’s unique autologous cellular implant derived from adipose tissue is produced with its SVF-2 device...

Learn More

Post

Interventional Orthopedics and Cell-based Medicine

A total knee replacement involves hours of surgery, a metal/polymer implant, and months of recovery. We prefer a minimally invasive approach that uses an injection instead of surgery, a cellular...

Learn More

Post

Initial safety and feasibility of cellular medicine therapy

Companies and clinics tout the promise of cellular medicine (usually as a "stem cell therapy") backed by little more than anecdotal evidence and the hypothetical possibility of efficacy. When we...

Learn More